OneSkin's OS-01 peptide: longevity breakthrough or clever branding?

What did @bella.dane actually say?

She made four core claims: that most anti-aging skincare lacks evidence, that OneSkin's OS-1 peptide was discovered after screening "over 900 peptides," that OS-1 is "the only peptide proven" to reduce senescent cells in skin, and that lips are "the leading facial attribute for perceived age" more than crow's feet. This is a paid partnership, which she flags with #OneSkinPartner, but she frames her endorsement around scientific credibility specifically. That framing is worth scrutinizing closely.

She also claims OS-1 "penetrates the skin and encourages healthy, younger cells to multiply, encourages collagen production, and strengthens skin barrier." Those are three distinct biological mechanisms, and lumping them together without distinguishing between in vitro and in vivo evidence is where the trouble starts.

Does the science back this up?

Partially, and with important caveats. OneSkin has published peer-reviewed work. A 2023 paper by Zonari et al. in npj Aging reported that OS-1 reduced markers of cellular senescence in 3D skin models and in a small human clinical trial. That's real. But "3D skin model" is not the same as your face, and the human trial was 12 weeks on 17 participants, which is underpowered by most clinical standards.

The senescence biology she references is legitimate science. Senescent cells do accumulate with age and do secrete pro-inflammatory signals, a phenomenon researchers call the senescence-associated secretory phenotype (SASP). Robbins et al. (2021, Nature Aging) confirmed that clearing senescent cells has systemic benefits in animal models. Whether a topical peptide achieves meaningful clearance in humans at cosmetic doses is a much harder question than the video implies.

On collagen production: GHK-Cu, a well-studied copper peptide, has documented collagen-stimulating effects (Pickart et al., 2015, Journal of Aging Research). OS-1 is a different peptide, and the collagen claims in the OneSkin literature rest largely on the same small studies.

What did they get wrong (or right)?

She got the senescence framework mostly right. The idea that senescent cells are a "pro-aging factor that affects all surrounding cells" is a fair plain-language summary of the SASP concept. Credit where it's due.

What she got wrong, or at least overstated, is the exclusivity claim. Saying OS-1 is "the only peptide proven to do this" ignores a substantial body of research on other peptides. Rapamycin, for instance, has shown senolytic-adjacent effects in skin (Liao et al., 2021, eLife). GHK-Cu has peer-reviewed data on skin barrier and collagen support. "Only proven" is a marketing sentence, not a scientific one.

The lip claim is the weakest link. The assertion that lips are "the leading facial attribute for perceived age more than your crow's feet" is cited nowhere in peer-reviewed literature I can find. Facial aging perception studies, including Zimbler et al. (2001, Archives of Facial Plastic Surgery), tend to focus on the periorbital region and nasolabial folds as primary age markers. This claim appears to originate from OneSkin's own marketing materials.

What should you actually know?

OneSkin is not a scam. It has done more published research than most cosmetic brands, and the OS-1 peptide has a legitimate scientific basis worth taking seriously. But "published" does not mean "proven at scale." The human trial data is preliminary. A 17-person study is a starting point, not a conclusion.

If you're interested in peptide-based skincare, the honest picture looks like this: topical peptides generally have difficulty penetrating the stratum corneum at therapeutic concentrations (Niren, 2006, Journal of Drugs in Dermatology). OneSkin claims OS-1 is designed to overcome this, which is plausible but not independently verified at scale. The patent exists, the publication exists, the effect sizes in small studies are real. The gap between early-stage research and the confident claims in this video is real too.

This is a paid partnership. That doesn't make the claims false, but it does mean you're watching someone whose financial incentive runs in one direction while her credibility pitch runs in another. Both things can be true at once.